Product Labeling and Safety Warnings
- Requires product inserts to include Black Box warnings on cardiovascular risks associated with celecoxib, etoricoxib, parecoxib, and valdecoxib.
- Mandates absolute contraindications for patients with prior stroke, heart attack, angioplasty, cardiac bypass graft, or uncontrolled hypertension.
- Advises warnings on potential cardiovascular class effects for all NSAIDs, including over-the-counter (OTC) drugs like ibuprofen, though not necessarily in Black Box format.
Manufacturer and Industry Obligations
- Requires submission of further safety data, including ongoing studies, to confirm whether cardiovascular risks are a class effect or specific to certain drugs.
Prescriber Guidelines
- Recommends using the lowest effective dose of COX-2 inhibitors for the shortest duration necessary.
- Encourages evaluating alternative therapies based on individual patient needs and risk factors.
- Emphasizes the need to balance gastrointestinal and cardiovascular risks before prescribing, especially in patients with heart disease risk factors.
- Cautions prescribers to be vigilant with patients having hypertension, hyperlipidemia, diabetes, smoking habit, or peripheral arterial disease.
- Declares absolute contraindication for COX-2 inhibitors in patients with history of heart attack, stroke, angioplasty, or CABG.
Patient Advisories
- Advises high-risk patients (prior heart attack, stroke, strong family history of heart disease, diabetes, smoking, hypertension, high cholesterol) to consult their doctors about discontinuing COX-2 inhibitors.
- Encourages all patients on COX-2 inhibitors to discuss alternative treatments with healthcare providers.
- Provides guidance on OTC NSAIDs usage: adhere strictly to label instructions and consult a physician if use exceeds ten days.
Specific Drug Actions and Recommendations
- Withdraws arthritis treatment indication for valdecoxib due to elevated cardiovascular event risk in cardiac bypass graft patients.
- Alerts prescribers about higher incidence of serious skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis) with valdecoxib and parecoxib; mandates immediate cessation upon skin or hypersensitivity symptoms.
- Advises cautious reintroduction of rofecoxib, if any, with stronger warnings and dose limitation to 12.5 mg from prior higher doses.
Regulatory Implementation
- The directives and advisories are effective as of April 4, 2005, under the authority of the BFAD Director, Prof. Leticia Barbara B. Gutierrez, M.S.